{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:22:10Z","timestamp":1791472930454,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:55:30Z","timestamp":1752616530000},"page":"447-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"9","author":[{"given":"Fabiano","family":"Flauto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2412-1310","authenticated-orcid":false,"given":"Giuseppe","family":"Neola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grillone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7205-5105","authenticated-orcid":false,"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.06.008_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.euo.2025.06.008_b0010","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.06.008_b0015","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.euo.2025.06.008_b0020","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.06.008_b0025","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/oncolo\/oyad102","article-title":"Visceral metastasis predicts response to new hormonal agents in metastatic castration-sensitive prostate cancer","volume":"28","author":"Yeked\u00fcz","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2025.06.008_b0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/path.4180","article-title":"Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases","volume":"230","author":"Akfirat","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.euo.2025.06.008_b0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10585-007-9116-4","article-title":"Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases","volume":"25","author":"Morrissey","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.euo.2025.06.008_b0040","doi-asserted-by":"crossref","first-page":"88211","DOI":"10.18632\/oncotarget.21085","article-title":"Molecular determinants of prostate cancer metastasis","volume":"8","author":"Rycaj","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2025.06.008_b0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the site of metastases on survival in patients with metastatic prostate cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urolo"},{"issue":"4S_Suppl","key":"10.1016\/j.euo.2025.06.008_b0050","first-page":"e170","article-title":"Predictors of early disease specific mortality among patients with prostate adenocarcinoma bone metastasis at diagnosis","volume":"197","author":"Klaassen","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.008_b0055","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JU.0000000000001568","article-title":"Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses","volume":"205","author":"Armstrong","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.008_b0060","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.008_b0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.008_b0070","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.008_b0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.008_b0080","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.008_b0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.008_b0090","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.008_b0095","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.06.008_b0100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euo.2025.06.008_b0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan - a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.euo.2025.06.008_b0110","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2025.06.008_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.euo.2025.06.008_b0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jphys.2020.07.003","article-title":"Clinimetrics: grading of recommendations, assessment, development and evaluation (GRADE)","volume":"67","author":"Xie","year":"2021","journal-title":"J Physiother"},{"key":"10.1016\/j.euo.2025.06.008_b0125","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.euo.2025.06.008_b0130","first-page":"974","article-title":"Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'?","volume":"28","author":"Drake","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.euo.2025.06.008_b0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5534\/wjmh.180040","article-title":"Role of androgen receptor in prostate cancer: a review","volume":"37","author":"Fujita","year":"2019","journal-title":"World J Mens Health"},{"key":"10.1016\/j.euo.2025.06.008_b0140","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.euo.2023.12.003","article-title":"Tumour-based mutational profiles predict visceral metastasis outcome and early death in prostate cancer patients","volume":"7","author":"Cussenot","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.06.008_b0145","doi-asserted-by":"crossref","unstructured":"Sharifi MN, Feng E, Rydzewski NR, et al. Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer. Mol Oncol. In press. https:\/\/doi.org\/10.1002\/1878-0261.70001.","DOI":"10.1002\/1878-0261.70001"},{"key":"10.1016\/j.euo.2025.06.008_b0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2025.06.008_b0155","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41585-024-00875-x","article-title":"From biology to the clinic - exploring liver metastasis in prostate cancer","volume":"21","author":"Ni","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.06.008_b0160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopha.2018.02.067","article-title":"Abiraterone acetate in the treatment of prostate cancer","volume":"101","author":"Thakur","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.euo.2025.06.008_b0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Pond","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.008_b0170","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2217\/fon.12.156","article-title":"Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario","volume":"8","author":"Caffo","year":"2012","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.06.008_b0175","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.11.026","article-title":"Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: a post-hoc exploratory analysis of the LATITUDE study","volume":"162","author":"Baciarello","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.06.008_b0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clgc.2020.06.001","article-title":"Treating de novo metastatic castration-sensitive prostate cancer with visceral metastases: an evolving issue","volume":"19","author":"Roviello","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.06.008_b0185","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.008_b0190","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.06.008_b0195","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:34:08Z","timestamp":1777602848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931125001889"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.008","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}